Why the study?
Does arterial stiffness measured by PWV associate with HFpEF and help identify at-risk intermediate phenotypes?
Does arterial stiffness measured by PWV associate with HFpEF and help identify at-risk intermediate phenotypes?
Pulse wave velocity (PWV) may serve as a clinically relevant tool to identify patients at risk for HFpEF by reflecting arterial stiffness driven by comorbidities.
May support PWV for HFpEF phenotyping; hypothesis-generating and requires prospective validation before practice change.
This study adds further support to the concept of HFpEF as a disease of the vasculature, underlined by an increasing arterial stiffness that is driven by vascular ageing and accumulating vascular comorbidities, for example, hypertension and diabetes. Reflecting a pulsatile arterial afterload associated with diastolic dysfunction and exercise capacity, PWV may provide a clinically relevant tool to identify at-risk intermediate phenotypes (e.g. pre-HFpEF) before overt HFpEF occurs.
No takes yet. Share an insight, caveat, or question.
Ali et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: